All posts by imreal

American College of Lifestyle Medicine Adds Enterprise-Connected Fitness and Health Platform FitRankings to its Corporate Roundtable


News Image

“Empowering tracking through a scalable solution such as FitRankings provides critical data for decision-making and optimal outcomes.”

The American College of Lifestyle Medicine (ACLM) has announced the addition of enterprise-connected health and fitness platform FitRankings to its Lifestyle Medicine Corporate Roundtable, a group of thought leaders and industry professionals who explore effective clinical innovations, activate marketing strategies, accelerate reimbursement and policy adoption, and pursue research and demonstrations of lifestyle medicine in practice. ACLM launched its Corporate Roundtable in 2016 and it now includes nearly 50 active member organizations in the lifestyle medicine ecosystem.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions as a primary modality to treat chronic conditions including, but not limited to, cardiovascular diseases, type 2 diabetes, and obesity. Lifestyle medicine certified clinicians are trained to apply evidence-based, whole-person, prescriptive lifestyle change to treat and, when used intensively, often reverse such conditions. Applying the six pillars of lifestyle medicine—a whole-food, plant-predominant eating pattern, physical activity, restorative sleep, stress management, avoidance of risky substances and positive social connections—also provides effective prevention for these conditions.

Some 92 percent of U.S. adults have a health app or wearable, but less than .01 percent of active lifestyle companies and organizations have the ability to connect to health apps or wearables. FitRankings Enterprise solution provides turnkey technology, tools and support that allow companies to connect universally to wearables and create authentic communities to drive positive health outcomes.

FitRankings’ solution can be implemented in minutes, with no engineering team or technical expertise needed. FitRankings serves many industries, including corporate wellness, active lifestyle brands, national governing bodies for sport and government entities.

“FitRankings’ mission is closely aligned with that of the ACLM,” said FitRankings Founder and CEO Patrick Hitchins. “FitRankings empowers active-lifestyle organizations with a turnkey platform, connected to wearables, that creates authentic digital communities around fitness and health. FitRankings hopes that our partnership with ACLM will allow more organizations to leverage the latest technology in their pursuit of healthier communities.”

“Physical activity is a key pillar of lifestyle medicine, and empowering tracking through a scalable solution such as FitRankings provides critical data for decision-making and optimal outcomes,” said ACLM President Cate Collings, MD, FACC, MS, DipABLM. “We welcome FitRankings to our Corporate Roundtable.”

ABOUT FITRANKINGS— Founded in 2015 and based in Austin, TX, FitRankings is the most advanced connected health and fitness platform for the enterprise. FitRankings gives organizations the ability to leverage the world of connected health devices by providing turnkey technology, tools, and support to create authentic digital fitness experiences and build scalable communities around health and fitness data. Learn more about FitRankings at fitrankings.com.

ABOUT ACLM–The American College of Lifestyle Medicine is the nation’s only medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence-based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

Share article on social media or email:

NeuroFlow Launches with 16th Air Force, Providing Wellness and Resiliency Resources to Airmen


NeuroFlow, the market leader in technology and services for behavioral health integration, has partnered with Sixteenth Air Force (Air Forces Cyber), to provide wellness and resiliency support and resources to Airmen.

The 18-month contract, which was awarded through TACFI, an innovation program within AFWERX, will focus on increased access to self-management tools and programs to optimize performance through daily health habits.

“Sixteenth Air Force is at the leading edge of intelligence and decision-making for the U.S. Air Force. They are a vital and resourceful organization that understands technology’s increasing role in the personal and professional lives of Airmen,” said NeuroFlow Chief Executive Officer and Army Veteran Chris Molaro. “We’re proud to partner with Air Forces Cyber to ensure those who seek help have access to tailored, private mental health resources and tools that they can use at their own discretion.”

Sixteenth Air Force, tasked with intelligence, surveillance, and reconnaissance, cyber, electromagnetic warfare, information operations, weather and information warfare for the U.S. Air Force can require Airmen to perform long hours of sustained concentration, which can take a mental toll without proper support. As more studies reveal the ‘intense emotional distress’ Airmen and other service members are under, and the increased awareness for suicide in military culture, steps are being taken to address the issue.

“NeuroFlow is a valuable tool in our armamentarium for resilience and improved mental health. This application helps to normalize mental health as part of a holistic approach to self-care and human performance enhancement,” said Col. Tracy Bozung, 16th Air Force Surgeon General. “Giving our Information Warfare Warriors the ability to work through mental health topics, ranging from sleep to mood, using validated questionnaires, is a significant advancement in ensuring the Airmen’s voices are heard and necessary resources are provided. It is a proactive approach to mental health care, tailored to an individual’s preferences and needs, available 24/7.”

In 2019, NeuroFlow began its initial work with the U.S. Air Force, at several bases, through an AFWERX contract. Through the partnership and the company’s unique triage engine, ‘urgent alerts’ triggered by in-app behavior helped to de-escalate incidents and even prevent instances of self-harm. This information remains anonymous and sits with a clinical response team, not battalion leaders.

“We’re at a place, socially, that is more empowering to speak about mental health and its impact on daily life, even job performance,” said NeuroFlow Vice President of Clinical Operations and Army Veteran Matt Miclette, MPH. “That same mentality needs to crossover into the military community. Technology gives us that much-needed ability to listen for a problem and activate the right resources for someone in crisis, before it becomes too late.”

About NeuroFlow

NeuroFlow assesses and triages people with behavioral health conditions to get them to the right level of care, providing high-tech and high-touch support for populations that would typically fall through the cracks in today’s healthcare system. Proven to drive better clinical and financial outcomes for hundreds of leading health systems, payors, and military organizations covering 15 million individuals, NeuroFlow’s platform combines consumer engagement with enterprise-level care management software to support behavioral health at scale. To learn more, visit http://www.neuroflow.com.

Share article on social media or email:

Hammes Healthcare breaks ground on BHSH Spectrum Health West Michigan Orthopedic and Performance Center


News Image

We look forward to successfully delivering these strategic projects for Spectrum Health.

Hammes Healthcare, a leading provider of consulting and project management services, broke ground on the new Orthopedic Health & Performance Center for Spectrum Health in Grand Rapids, Michigan on September 27.

Hammes is servings as owner’s representative for the new 117,000-square-foot orthopedic facility that will provide advanced orthopedic care, an ambulatory surgery center, physician and occupational therapy, performance training spaces, and orthopedic urgent care. The Orthopedic Health & Performance Center is expected to open in 2024.

Hammes is also serving as the owner’s representative for Spectrum Health’s new 240,000-square-foot ambulatory care building in Grand Rapids, which broke ground in July.

“We believe our ability to concurrently manage multiple, large-scale projects for health systems is one of our key strengths,” said Nancy Connolly, President of Hammes Healthcare. “We look forward to successfully delivering these strategic projects for Spectrum Health.”

About Hammes Healthcare

Hammes Healthcare is a national consulting firm that provides real estate and market strategy, facility planning, project management and development services to the healthcare industry. As a reflection of its commitment to the healthcare industry, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 24 consecutive years—including 19 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Hammes has managed in excess of 57 million square feet of complex new, expansion, renovation, replacement, ambulatory care, and acute care projects with a value of more than $23 billion for hospitals and health systems nationwide. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. https://www.hammes.com/

Share article on social media or email:

St. Joe’s partners with MOLLI Surgical to treat breast cancer patient with new surgical technology


News Image

A 74-year-old Hamiltonian is one of the first breast cancer patients at St. Joseph’s Healthcare Hamilton to be treated with a new technology that pinpoints cancer’s precise location.

In the past, St. Joe’s radiologists would insert a low-dose radioactive marker or a small wire into the abnormal tissue of breast cancer patients. These interventions can be uncomfortable and there may be anxiety due to the use of a radioactive marker. But now, the MOLLI Marker® — the size of a sesame seed — is implanted to mark a patient’s lesion, eliminating safety concerns from radiation and creating a more comfortable experience.

This new technique allows St. Joe’s surgeon Dr. Peter Lovrics to create a smaller incision and better target the cancer cells. Since May 2022, MOLLI® has been used for all localization procedures by St. Joe’s due to its ease of use and improved experiences for doctors and patients.

“MOLLI is improving the breast cancer treatment experience for both patients and clinicians,” said Dr. Lovrics. “Because it is more advanced at localizing cancers, people with breast cancer can feel more at ease knowing that their surgery will be easier, faster and more precise. We hope to introduce MOLLI throughout the region as a way of moving past radioactive seed technology, and incorporate its use into other soft-tissue cancer treatment.”

The 74-year-old patient, Angela Alexander-Roper, credits her swift recovery, virtual absence of pain, small bruise and a tiny upside-down smile scar to MOLLI.

“Finding the lump was one of the most frightening things I’ve experienced. I’m very grateful to anybody who had any part in creating the seed and making it accessible for people with breast cancer,” she said. “It went directly in; Dr. Lovrics was able to cut the tissue and get all the margins. He was even able to tell my husband straight away that they had got it all. Afterward, Dr. Lovrics told me, ‘Go ahead, live your life!’ and it was all because of that little marker.”

After a short but frightening experience facing cancer for the first time, Angela is now looking forward to continuing spending time with her four children and 13 grandchildren, and going on holiday with her husband in October.

“St. Joe’s is committed to building a breast diagnostic centre of excellence,” said Dr. Lovrics. “With the help of our technology partners like MOLLI Surgical and others, and the support of our community, we’ll be able to improve outcomes for the patients we serve.”

MOLLI Surgical’s Health Canada approved and FDA-cleared MOLLI features the smallest localization marker on the market that can be used with all soft tissues. MOLLI Surgical is looking forward to applying the benefits of this technology beyond breast disease. The MOLLI Wand® detects the MOLLI Marker — much like a GPS — helping surgeons pinpoint lesions more efficiently and with improved accuracy, translating into better surgical options and an improved experience for all before, during and after surgery.

“MOLLI has significantly decreased stress in our patients,” said Dr. Colm Boylan, Chief of Diagnostic Imaging at St. Joe’s. “The process is simpler, more efficient and requires fewer staff to be present, which creates a calm environment. We know that many patients with radioactive markers experienced anxiety due to risks of radiation emissions. They often avoided contact with family, whom they need for support. MOLLI is a tremendous advancement for treating one of the most common cancers affecting Canadians.”

Right now, the hospital is working with St. Joseph’s Healthcare Foundation to actively raise funds for vital medical equipment that will create a one-stop centre of excellence that supports patients with breast cancer every step of the way — from diagnosis to treatment to recovery and remission. Funds raised will help purchase essential technology, including Contrast Enhanced Mammography and MRI Breast Coils, to enhance the detection of breast cancer more definitively and at its earliest stages so that patients like Angela will get the answers they need sooner, and have the best possible health outcome.

Quotes:

“We are excited to partner with St. Joseph’s Healthcare Hamilton, an academic hospital with a well-known culture of innovation, whether in their deep experience treating patients with breast disease or their dedication to surgical innovation. We are so pleased to hear that future surgeons find MOLLI® so intuitive, so easy to use and accurate, that trainees have mastered its use very quickly.”

Ananth Ravi, PhD

President and CEO of MOLLI Surgical Inc.

“St. Joe’s has earned a national reputation for outstanding patient care and innovative medical and surgical treatments. MOLLI® is a great fit for us as we switch away from radioactive seed technology, because it makes precision surgery simpler. We’re also leaders in bringing innovation and best practices out to our whole community of hospitals so no matter where a patient lives in the Hamilton-Niagara Region — in an urban or rural area — they have access to the latest and best treatments, outcomes, and experience. With the right partnerships and the right technology, we can do great things for patients.”

Rick Badzioch

Vice President, Clinical Programs, St. Joe’s

About St. Joseph’s Healthcare Hamilton:

St. Joseph’s Healthcare Hamilton (SJHH) is a leading research and academic health science centre located in the heart of Hamilton, Ontario. The Hospital is particularly well known for excellence in virtual care, mental health and addictions, respiratory care, kidney and urinary care, robotic surgical services, cancer surgery and women’s and infants’ care. The hospital’s threefold mission is to provide dynamic research, revolutionary methods in health sciences education, and the highest standard of clinical care in a spirit of compassion and innovation. SJHH is a member of the St. Joseph’s Health System, working in close partnership with St. Joseph’s Villa Dundas for long-term care, and St. Joseph’s Home Care. You can connect with SJHH on Twitter, LinkedIn, Facebook, or Instagram.

About MOLLI Surgical:

MOLLI Surgical started in the operating room, where surgeons were using dated tools to treat cancer patients — and we knew we could do better. Our surgical wand is precise, easy-to-use and built with the realities of the operating room in mind. More importantly, it is built with patients in mind. Our technology replaces procedures to mark lesions with one that is more precise, efficient and cost-effective. MOLLI Surgical is proud to build the advanced equipment that patients prefer to have and that physicians prefer to use. Follow us on Facebook, LinkedIn, Twitter, and YouTube.



The Plastic Surgery Foundation receives FDA approval to conduct multicenter study of ADM and surgical mesh used in breast reconstruction


News Image

Oct. 13, 2022— Arlington Heights, IL. The Plastic Surgery Foundation (PSF) received approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption (IDE) application and will now proceed as sponsor of a prospective, multicenter observational trial studying the impact of acellular dermal matrix (ADM) and surgical mesh in implant-based breast reconstruction.

“These devices should be rigorously evaluated in relation to surgical technique, device loss, complications, and aesthetic and patient-reported satisfaction outcomes,” says The PSF President Bernard Lee, MD, MPH, MBA, who is a co-principal investigator (co-PI) of the study. “The PSF has assumed an important leadership role by undertaking this study.”

“An approved protocol is an essential first step to executing a clinical trial capable of providing manufacturers with the level of high-quality scientific evidence needed to submit a Premarket Approval Application (PMA) to the FDA,” adds Gayle Gordillo, MD, who is also a co-PI of the study. “This action can further gauge the safety and effectiveness for patient use.”

Surgical mesh devices – whether synthetic, animal or human collagen-derived – have not yet received FDA approval for any breast reconstruction indication. However, ADMs and surgical meshes can be marketed and promoted for other approved uses, such as soft-tissue reinforcement. Currently, surgeons, hospitals and other facilities may elect to use these devices in breast reconstruction or other breast surgery via “off-label” use.

The PSF is currently working with Dr. Lee, Dr. Gordillo and Scot Glasberg, MD, executive sponsor of the IDE, to finalize execution details for the study and enable site recruitment. Due diligence and funding discussions are underway with many manufacturers regarding participation. The PSF anticipates its first patient enrollments in early 2023.

“This is strictly an observational study,” says Dr. Glasberg. “Since these devices have been used in this manner for approximately 17 years and have become the standard of care, The PSF will not ask surgeons to randomize their patients or change their usual practice of medicine in terms of the procedures or devices they use. Limiting surgeons to participation in a single study or control arm will eliminate bias associated with investigators deciding in which arm to place each patient – for example, placing patients with a greater risk profile in the subpectoral or device study groups. We are grateful that the FDA has recognized this approach as necessary to adequately fill all study arms.

“The PSF’s partnership with FDA on this study will hopefully finally yield approval for these important devices in breast reconstruction surgery,” Dr. Glasberg adds.

The PSF invites manufacturers interested in partnering in this study to submit a supplemental IDE package to request FDA approval to participate. The PSF will recruit sites to fill the two non-ADM/mesh control arms, which will be used as the comparator for all of the device study arms.

Those interested in learning more about this study or partnering with The PSF are encouraged to contact Gina T. McClure, executive director of The Plastic Surgery Foundation, at gmcclure@plasticsurgery.org.

About The PSF

The Plastic Surgery Foundation (The PSF) supports the research and international activities of the American Society of Plastic Surgeons (ASPS) members. The PSF works alongside ASPS to support the innovators’ idea, teaches researchers how to articulate the relevancy, the impact, and the possibilities that their ideas hold, works to bring the right people together so that the tested and meaningful idea can reach the marketplace and helps a cadre of volunteers take those new ideas and tried and true procedures to all corners of the world to help people.

Share article on social media or email:

ALS Association Announces Creation of Stephen Kauffman ALS Superfan Award


Stephen Kauffman, who is living with ALS, was honored by the Naismith Memorial Hall of Fame as a “Superfan” of the Golden State Warriors

“Stephen Kauffman has shown how being a Superfan can inspire a community and enable someone living with ALS to transcend even the most devastating of diagnoses,” said Calaneet Balas, President and CEO of the ALS Association.

Award Named After Golden State Warriors Fan Living with ALS Who Was Honored by Naismith Memorial Basketball Hall of Fame

The ALS Association today announced the creation of a new award to honor “Superfans,” the most passionate sports and entertainment fans who are also living with ALS. The award is inspired by Stephen Kauffman, who was diagnosed with ALS in 2012, and was honored in 2021 by the Naismith Memorial Basketball Hall of Fame as a Golden State Warriors “Superfan.” The ALS Superfan campaign is aiming to raise $1 million with 100% of proceeds going directly to ALS research.

“Stephen Kauffman has shown how being a Superfan can inspire a community and enable someone living with ALS to transcend even the most devastating of diagnoses,” said Calaneet Balas, President and CEO of the ALS Association. “The Stephen Kauffman ALS Superfan campaign will enable us to honor the most devoted sports and entertainment fans, while generating new funds dedicated to the search for new treatments and cures.”

To kick off the campaign, the ALS Association has launched an auction featuring one-of-a-kind sports memorabilia, experiences, and several other items. All proceeds from the auction – which closes at 9 p.m. ET on October 20 — will go directly to ALS research. You can make a donation or bid on an auction item here.

“I’m honored and grateful for this recognition and glad that the campaign will help fund much-needed ALS research,” said Stephen. “I have always been a sports fan and have been lucky to have a front row seat for four Golden State Warriors championships, whether in the arena or at home in front of the television. I’m thankful for all the members of the Warriors staff and community who have supported me over the years.”

Added Stephen: “I would love for this award to honor sports fans of all backgrounds who are fighting ALS.”

The Golden State Warriors sponsored a private event in the Bay Area honoring Stephen.

Stephen’s father Scott is chair of the ALS Association Board of Trustees and serves as a caregiver for Stephen.

“Throughout this horrific journey known as ALS, our family’s shared love of the Golden State Warriors has kept us all going,” said Scott. “There’s no doubt that many other families living with ALS share a similar bond around a favorite team, athlete, or entertainer. We’re humbled and grateful that this campaign will honor Stephen while also supporting the urgent work to end ALS.”

The first recipient of the Stephen Kauffman ALS Superfan Award will be announced in Spring 2023. Future recipients will be honored on an ongoing basis. If you know of a Superfan who is living with ALS and deserves to be recognized, please email superfan@als.org.

About ALS

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. Over the course of the disease, people lose the ability to move, to speak, and eventually, to breathe. On average, it takes about a year before a final ALS diagnosis is made. The disease is always fatal, usually within five years of diagnosis. There is no cure.

About The ALS Association

The ALS Association is the largest philanthropic funder of ALS research in the world. The Association funds global research collaborations, assists people with ALS and their families through its nationwide network of care and certified clinical care centers, and advocates for better public policies for people with ALS. The ALS Association is working to make ALS a livable disease while urgently searching for new treatments and a cure. For more information about The ALS Association, visit our website at http://www.als.org.

Share article on social media or email:

Nikki Porcher Is Running The NYC Marathon For Black Women


Nikki Porcher founder of nonprofit organization Buy From A Black Woman

Nikki Porcher, founder of nonprofit organization Buy From A Black Woman, shatters limitations set by others with every marathon that she runs. (Photo Credit: Lynsey Weatherspoon)

“I’m grateful and honored to be running the New York City Marathon for Black Women business owners. Black Women are so deserving.”

Nikki Porcher, founder of nonprofit organization Buy From A Black Woman, is running the New York City Marathon for Black women business owners. Buy From A Black Woman is an official charity partner of TCS New York City Marathon and Porcher is running as a charity runner for the nonprofit.

“I’m grateful and honored to be running the New York City Marathon for Black Women business owners. Black Women are so deserving,” says Porcher.

“And I hope to inspire others because I was told that I’d never be able to run for long periods of time. As Black Women we’re often told what our limitations are. The only limits I have are the ones I put on myself,” she adds.

In 2013, Porcher shattered her kneecap and after having surgery, doctors said she would walk with a limp and never be able to run for long periods. So, she started running half marathons, and then half marathons in different states. She set a goal to run in all 50 states and has crossed 15 off her list so far.

Porcher was actually inspired to create Buy From A Black Woman while traveling for a half marathon in 2015. She missed her flight, decided to go shopping and ended up in a marketplace with no Black Women vendors.

“It was here that I discovered what my real purpose is. I was the only Black Woman in the room, which led to me blogging and then starting a nonprofit. So, I’m not only running this marathon, but I’m running as a charity runner for a nonprofit I created because I missed my flight heading to run a marathon. It doesn’t get more full circle than this,” Porcher shares.

Buy From A Black Woman is now one of the largest communities of Black Women business owners across the globe. The nonprofit provides educational programs, funding, and an online directory that makes Black Women-owned businesses easier to find.

The charitable organization equips Black Women with the tools and resources they need to be successful. You can support their efforts by donating to their fundraiser for the NYC Marathon, or by volunteering with their community for the event.

Buy From A Black Woman will also be taking over Mile 16 water station and hosting a party on the pavement to celebrate all the runners who are running that day.

To learn more about the nonprofit, visit BuyFromABlackWoman.org.

About Buy From A Black Woman

Buy From A Black Woman ensures that Black Women have the tools and resources that will allow them to be successful. Through educational programs, an online directory, and financial support, this trusted resource for Black Women in business across the country and around the globe continues is quickly becoming the largest community of Black Women Business Owners.

Founded in 2016 by Nikki Porcher, Buy From A Black Woman is a 501(c)3 that empowers, educates, and inspires Black Women Business Owners and the people who support them. When you support a Black Woman Business Owner, you support a whole community.

Share article on social media or email:

AATOD Announces Worldwide Gathering of Policy Makers and Opioid Addiction Treatment Experts to be Held in Baltimore


https://youtu.be/IqPDgrwPiOs

AATOD Conference Commercial

“Our nation continues to face the deadly public health challenge of opioid use disorder, especially driven by fentanyl, which accounts for more than 65% of reported mortality rates,” said Mark Parrino, M.P.A., President of AATOD.

The American Association for the Treatment of Opioid Dependence (AATOD) is convening its major Conference in Baltimore, Maryland at the Baltimore Hilton Inner Harbor, October 30 – November 3, 2022. This conference will feature numerous sessions — preconference, workshop, plenary and poster — on a municipal, state, national and international level, focusing on current and changing policy and new clinical findings with regard to the treatment of opioid use disorder (OUD). More than 1,200 treatment providers and opioid addiction policy officials from every state in the country will focus on solutions for dealing with the soaring public health epidemic of opioid addiction in the United States, including its intersection with the Coronavirus pandemic.

The U.S. recently passed the benchmark of 100,000 deaths over a 12-month period from accidental drug overdose (OD). This opioid epidemic began with prescription opioid misuse, which morphed into heroin use and, at present, to increased fentanyl use. Our country has also entered an era of increased stimulant use, particularly with methamphetamine. The COVID-19 pandemic brought about several temporary changes to the way medication-assisted treatment (MAT) for OUD, including methadone administration, is provided to patients through our nation’s opioid treatment programs (OTPs). Currently there is widespread discussion and controversy about what changes should be made permanent and what other changes should be considered.

The hosts of the 2022 meeting, “The Power of Collaboration,” are the Opioid Treatment Providers of Maryland and the Maryland Department of Health — Behavioral Health Administration. The meeting will have an opening from Rahul Gupta, MD, Director of the White House Office of National Drug Control Policy (ONDCP) and will conclude with a presentation from Miriam E. Delphin-Rittmon, Ph.D., the HHS Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health Services Administration (SAMHSA).

“Our nation continues to face the deadly public health challenge of opioid use disorder, especially driven by fentanyl, which accounts for more than 65% of reported mortality rates,” said Mark Parrino, M.P.A., President of AATOD. “We are increasing access to opioid treatment programs throughout the United States in addition to increasing the use of mobile treatment vans and brick and mortar medication units. It is important to draw upon evidence when increasing access to good quality and well-coordinated care and these will be featured topics during our Conference. We also need to develop a public education campaign about opioid use disorder and its effective treatment.”

The AATOD Conference is the largest gathering of the opioid treatment community. This conference comes at a critical time for the U.S. and Baltimore, in particular, which is home to one of the first OTPs in the country, Man Alive/Lane Treatment Center, and has expanded its treatment network to nearly 40 OTPs over the past 50 years as the need for effective OUD treatment has grown. This includes a mix of freestanding, hospital and justice-based facilities, as well as for- and not-for-profit programs. During the proceedings, the World Federation for the Treatment of Opioid Dependence, of which AATOD is a member, will also convene a major meeting on Monday, October 31, 2022.

“Now more than ever, with highly potent opioids on the streets, and with increasing social and mental health problems in part stemming from the COVID pandemic and economic struggles, people with opioid use disorder need comprehensive treatment to fully recover,” said Kenneth B. Stoller, MD, DLFAPA, Associate Professor, Johns Hopkins University School of Medicine and Conference Chair. “This requires a collaborative approach. The gathering in Baltimore, a stone’s throw from our federal oversight partners, is an opportunity for treatment providers, related fields such as social services and criminal justice, and policymakers, to learn together and forge productive connections.”

“Maryland Department of Health is committed to increasing access to evidence-based harm reduction and treatment practices, including the use of effective medications, to help address the opioid crisis,” said Kathleen Rebbert-Franklin, Director of Service Access and Practice Innovation for the Maryland Department of Health’s Behavioral Health Administration. “This conference offers providers from many service settings the most current research and treatment information that will further enhance their practices and improve care in Maryland.”

Featured speakers will include:

· Tuesday, November 1 — Robin E. Rickard, JD, Executive Director, Opioid Operational Command Center, Crownsville, MD; Mark W. Parrino, MPA, President, AATOD; Rahul Gupta, MD, MPH, MBA, FACP, Director of the White House Office of National Drug Control Policy (ONDCP). Moderated by Kenneth B. Stoller, MD, DLFAPA, Director, Johns Hopkins Broadway Center for Addiction; Associate Professor, Department of Psychiatry, Johns Hopkins University School of Medicine.

· Wednesday, November 2 — Kathleen Rebbert-Franklin, LCSW-C, Director, Service Access and Practice Innovation, Maryland Department of Health, Behavioral Health Administration, Catonsville, MD; Babak Imanoel, DO, Medical Director, Northern Parkway Treatment Services, Baltimore, MD; Gregory Branch, MD, MBA, CPE, Health Officer and Director, Baltimore, MD. Moderated by Vickie Walters, LCSW-C, Executive Director, Institutes for Behavior Resources, Inc, Baltimore, MD.

· Thursday, November 3 — Miriam E. Delphin-Rittmon, Ph.D., the HHS Assistant Secretary for Mental Health and Substance Use and the leader of the Substance Abuse and Mental Health Services Administration (SAMHSA). Moderated by Mark Parrino/AATOD.

An advance copy of the full conference program, which will be made available to attendees onsite, can be found here: https://www.eventscribe.net/2022/AATOD/agenda.asp?pfp=FullSchedule Conference hashtag: #aatod2022

About AATOD

The American Association for the Treatment of Opioid Dependence (AATOD) was founded in 1984 to enhance the quality of patient care in treatment programs by promoting the growth and development of comprehensive opioid treatment services throughout the United States. AATOD represents more than 1,200 Opioid Treatment Programs in the United States. AATOD has thirty state chapters and is also a founding partner in the development of the World Federation for the Treatment of Opioid Dependence, which represents another 600 treatment programs throughout Europe. The World Federation has special consultative status with the United Nations. Accordingly, AATOD actively works with the United Nations Office on Drugs and Crime and other agencies in order to provide access to opioid addiction treatment wherever it is needed in the world. For more information visit http://www.aatod.org. Find AATOD on Facebook, Instagram and Twitter: @aatod1984.

Contact:

Mark W. Parrino, M.P.A

President, AATOD

212.566.5555, x200

Mark.Parrino@aatod.org

Bill Gordon

PR/Media Relations

646-924-6146

Billgordon37@hotmail.com

Eagle Telemedicine Names Caryn Bremer Vice President, Licensing and Credentialling


Eagle Telemedicine

Eagle is perfectly positioned to deliver the specialized inpatient physician services today’s health systems so desperately need during a pivotal time of staffing shortages in our healthcare industry.

Eagle Telemedicine, the leader in technology-enabled inpatient care for sustainable healthcare resilience, today announced that it has added Caryn Bremer as Vice President, Licensing and Credentialing. A medical industry customer service leader, Bremer brings decades of operational, customer service and physician training and services expertise to the Eagle team.

“Caryn has extensive experience in delivering valuable process improvements and provider training programs that inspire physician productivity and engagement,” said Jason Povio, President and Chief Operating Officer, Eagle Telemedicine. “Her track record of licensing and credentialing success will help accelerate our growth into new regional markets and practice areas. It’s an honor to welcome such a visionary leader to the Eagle team.”

Bremer joins Eagle from IN Compass Health where she most recently served as Vice President of Physician Services. During her 20-year tenure at IN Compass Health, she served as a Med-Mal claims management liaison, developed training processes for providers and staff, and has implemented hospitalist programs throughout the U.S. Key among her responsibilities was to activate provider credentialing and privileges, build compliance programs for efficient claims management and educate patients and primary care physicians on hospitalist services. Prior to IN Compass Health, Bremer served in healthcare training and operations leadership roles with Predict/Just Medicine, Simione Central National, Central Home Health Services and Dekalb Medical Center. Bremer was a psychology major at Georgia State University.

“Eagle is perfectly positioned to deliver the specialized inpatient physician services today’s health systems so desperately need during a pivotal time of staffing shortages in our healthcare industry,” said Bremer. “Attracting and retaining skilled physicians is more challenging than ever. By expanding the reach of telemedicine to support the hospitals requirements both regional and metropolitan hospitals have, Eagle is making a significant difference in patient outcomes across the nation. I am thrilled to join such a talented team and look forward to bringing my years of experience optimizing physician productivity and licensing compliance to help further Eagle’s expansion.”

As Eagle’s Vice President, Licensing and Credentialing, Bremer reports directly to Povio.

About Eagle Telemedicine

Eagle Telemedicine is the leader in technology-enabled inpatient care for sustainable healthcare resilience. With a virtual team of more than 300 physicians in more than 15 specialties, Eagle delivers care services that improve patient outcomes, mitigate coverage gaps, expand specialty access and help hospitals enhance care quality and reputation in the communities they serve. With a world-class “webside” manner, Eagle physicians deliver custom-tailored round-the-clock coverage, leveraging existing technologies and processes, for a truly seamless patient experience. Committed to building relationships, not delivering transactions, Eagle empowers rural and metropolitan hospitals alike to increase admissions, expand service access and lower patient transfer rates. For more information, visit http://www.eagletelemedicine.com or follow us on LinkedIn.

Share article on social media or email:

Has your distributor discontinued their kits and chromogenic substrates? Haven’t found the right product line? Aniara Diagnostica has them available!!


News Image

The entire Aniara line is available for purchase at http://www.aniara.com.

Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today’s highest standards for product quality and cost-efficient delivery.

For Research Use Only. Not for Use in Diagnostic Procedures.

Specific kits are USP/EP compliant for Quality Control testing.

USP/EP Compliant Heparin QC Kits Chromogenic Anti-IIa and Anti-Xa methods are used for measuring homogeneous Heparin for Quality Control.

BIOPHEN Heparin Anti-IIa (2 stages) A220005 click here for more information

BIOPHEN Heparin Anti-Xa (2 stages) A221005 click here for more information

Heparin Anti-IIa (Kinetics) BIOPHEN™ Heparin Anti-IIa (Kinetics) is a method for measuring Heparin in purified systems.

BIOPHEN Heparin Anti-IIa (kinetics) A221020 click here for more information

Chromogenic Substrates: Thrombin Chromogenic Substrates for use in the Anti-IIa assay for Quality Control.

BIOPHEN™ CS-01(38) Thrombin (1 x 25mg) A229001 click here for more information

BIOPHEN™ CS-01(38) Thrombin (12 x 25mg) A229001C click here for more information

Chromogenic Substrates: Factor Xa Factor Xa Chromogenic Substrates for use in the Anti-Xa assay for Quality Control.

BIOPHEN™ CS-11(22) Factor Xa (1x25mg) A229015 click here for more information

BIOPHEN™ CS-11(65) Factor Xa (1 x 25mg) A229014 click here for more information

BIOPHEN™ CS-11(65) Factor Xa (12 x 25mg) A229014C click here for more information

BIOPHEN™ CS-11(32) Factor Xa Chromogenic substrate A229011 click here for more information

BIOPHEN™ CS-21(66) Activated Protein C Chromogenic Substrate A229021 click here for more information

BIOPHEN™ CS-41(03) Plasmin and Plasminogen-SK Chromogenic substrate A229041click here for more information

Purified Human Protein: Anti-Thrombin (AT) Human Anti-Thrombin for Quality Control including studies on Heparin and other glycoaminoglycans (GAGs).

Anti-Thrombin (AT) (1 x 1.5 mg) APP004B click here for more information

Anti-Thrombin (AT) (10 x 1.5 mg) APP004L click here for more information

Anti-Thrombin (AT) (1 x 3.75 mg) APP004D click here for more information

Anti-Thrombin (AT) (10 x 3.75 mg) APP004M click here for more information

Anti-Thrombin (AT) (1 x 10 mg) APP004C click here for more information

Purified Human Protein: Thrombin Purified Human α-Thrombin for use in Anti-IIa assays for Quality Control.

Human Thrombin 1 x 10 NIH AEZ006O click here for more information

Human Thrombin 6 x 10 NIH AEZ006K click here for more information

Human Thrombin 1 x 100 NIH AEZ006A click here for more information

Human Thrombin 10 x 100 NIH AEZ006L click here for more information

Human Thrombin 1 x 1000 NIH AEZ006B click here for more information

Purified Bovine Enzyme: Factor Xa Purified Bovine Factor Xa for use in Anti-Xa assays for Quality Control of Heparin and other glycoaminoglycans (GAGs).

Purified Bovine Factor Xa (1 x 30 µg) ABE101D click here for more information

Purified Bovine Factor Xa (10 x 30 µg) ABE101L click here for more information

Buffers Used for USP/EP Heparin QC Assays Buffers for use in the Anti-IIa and Anti-Xa quality control assays are compliant with US and European Pharmacopeia monographs.

USP Heparin BSA Buffer without PEG (1L) – pH 8.4 A12-0017 click here for more information

USP Anti-Factor Xa Activity Buffer (1L) – pH 8.4 A12-0018 click here for more information

Tris-NaCI Buffer, with Albumin – (pH 7.4) AAR005L click here for more information

Tris-NaCI Buffer – (pH 7.4) AAR028K click here for more information

Tris EDTA NaCI Buffer -( pH 8.4) AAR029K click here for more information

Tris NaCI EDTA PEG Buffer – (pH 8.4) AAR030K click here for more information

Tris NaCI EDTA BSA buffer – (pH 8.4) AAR031K click here for more information

Click the link to see a competitor comparison

Literature (aniara.com)

The entire Aniara product line is available for purchase at http://www.aniara.com. The Company distributes products in North America, Sweden, Norway, Denmark, Finland, Lithuania, Latvia, Estonia and Iceland.

Share article on social media or email: